Location History:
- Shanghai, CN (2022)
- Hubei, CN (2017 - 2023)
Company Filing History:
14 out of 14 
5 out of 5 
1 out of 1 Years Active: 2017-2025
Title: Innovations of Chaodong Wang in Triazole Compounds
Introduction
Chaodong Wang is a prominent inventor based in Hubei, China, known for his significant contributions to the field of pharmaceutical chemistry. He holds a total of 13 patents, showcasing his innovative approach to developing compounds with therapeutic potential.
Latest Patents
Wang's latest patents include groundbreaking work on triazole compounds and their preparation methods. These compounds exhibit excellent LPAR1 antagonistic activity and selectivity, with low toxicity and good metabolic stability. They are promising candidates for preventing or treating LPAR1-related diseases or disorders. Notably, the IC50 values of some triazole compounds can be as low as 50 nM, indicating their potency. Additionally, the compounds demonstrate a CC50 value range greater than 200 μM, along with good metabolic stability in humans, fancy rats, and house mice. Another significant patent involves lysophosphatidic acid receptor antagonists, which also show high LPAR1 antagonist activity and selectivity, low toxicity, and promising pharmaceutical development prospects.
Career Highlights
Chaodong Wang has worked with notable companies such as Wuhan LL Science and Technology Development Co., Ltd. and Wuhan QR Pharmaceuticals Co., Ltd. His work in these organizations has contributed to the advancement of pharmaceutical research and development.
Collaborations
Wang has collaborated with esteemed colleagues, including Yongkai Chen and Wei Feng, further enhancing the impact of his research in the field.
Conclusion
Chaodong Wang's innovative work in the development of triazole compounds and lysophosphatidic acid receptor antagonists highlights his significant contributions to pharmaceutical science. His patents reflect a commitment to advancing medical treatments and improving patient outcomes.